Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels
- PMID: 31190584
- DOI: 10.1080/00365521.2019.1624815
Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels
Abstract
Objectives: Irritable bowel syndrome (IBS) may be associated with disturbances in gut microbiota composition and functions. We recently performed a study of fecal microbiota transplantation (FMT) in diarrhea-predominant IBS (IBS-D) and found that IBS symptoms improved and the gut microbiota profile changed following FMT. We now aimed to explore the effects of FMT on the gut microenvironment in further detail by using 16S rRNA sequencing for more extended microbiota profiling and analyzing bacterial fermentation products (SCFAs: short chain fatty acids). Materials and methods: The study included 13 patients (four females and nine males) with IBS-D according to Rome III criteria and 13 healthy donors. Freshly donated feces were administered into duodenum via gastroscopy. The patients completed symptom and quality of life (QoL) questionnaires and delivered feces before and 1, 3, 12 and 20/28 weeks after FMT. Microbiota analysis was performed by sequencing 16S rRNA gene with Illumina Miseq technology. Fecal concentrations of SCFAs were analyzed by vacuum distillation followed by gas chromatography. Results: Several gut microbiota taxa and SCFAs were significantly different in the patients at baseline compared to their donors. These differences normalized by the third week following FMT in parallel with significant improvement in symptoms and QoL. Responders had different gut microbiota profile and SCFAs than nonresponders. Significant correlations were found between the gut microenvironment and IBS symptoms. No adverse effects were reported. Conclusions: FMT restores alterations of the gut microenvironment in IBS-D patients during the first 3 weeks and improves their symptoms for up to 28 weeks. ClinicalTrials.gov ID: NCT03333291.
Keywords: 16S rRNA sequencing; Bacterial fermentation products; FMT; IBS; correlations; gut microenvironment; manipulation; transplantation.
Similar articles
-
The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.Front Cell Infect Microbiol. 2021 May 12;11:524851. doi: 10.3389/fcimb.2021.524851. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34055657 Free PMC article.
-
The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation.PLoS One. 2018 Nov 14;13(11):e0194904. doi: 10.1371/journal.pone.0194904. eCollection 2018. PLoS One. 2018. PMID: 30427836 Free PMC article.
-
Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome.Neurogastroenterol Motil. 2021 Feb;33(2):e13983. doi: 10.1111/nmo.13983. Epub 2020 Sep 17. Neurogastroenterol Motil. 2021. PMID: 32945066 Free PMC article. Clinical Trial.
-
Fecal microbiota transplantation in patients with irritable bowel syndrome: an overview of current studies.J Appl Microbiol. 2023 Mar 1;134(3):lxad044. doi: 10.1093/jambio/lxad044. J Appl Microbiol. 2023. PMID: 36882216 Review.
-
A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome.BMC Gastroenterol. 2024 Jul 5;24(1):217. doi: 10.1186/s12876-024-03311-x. BMC Gastroenterol. 2024. PMID: 38970007 Free PMC article.
Cited by
-
Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study.Microorganisms. 2023 Jan 20;11(2):277. doi: 10.3390/microorganisms11020277. Microorganisms. 2023. PMID: 36838241 Free PMC article.
-
The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.Front Cell Infect Microbiol. 2021 May 12;11:524851. doi: 10.3389/fcimb.2021.524851. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34055657 Free PMC article.
-
Evaluation of two laboratory model methods for diarrheal irritable bowel syndrome.Mol Med. 2023 Jan 12;29(1):5. doi: 10.1186/s10020-022-00599-x. Mol Med. 2023. PMID: 36635623 Free PMC article.
-
Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases.J Clin Med. 2022 Jul 15;11(14):4119. doi: 10.3390/jcm11144119. J Clin Med. 2022. PMID: 35887883 Free PMC article. Review.
-
Impacts of Gut Microbiota on the Immune System and Fecal Microbiota Transplantation as a Re-Emerging Therapy for Autoimmune Diseases.Antibiotics (Basel). 2022 Aug 12;11(8):1093. doi: 10.3390/antibiotics11081093. Antibiotics (Basel). 2022. PMID: 36009962 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical